Werewolf Therapeutics, Inc.
HOWL · XNASCIK 1785530fmd_1KVJ8V13N1R2MXA4RT2BQEW91RManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Jun 30, 2026, 26 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 17 | 35 | 54 | 42 | 56 | 45 |
| Total operating expenses | 22 | 50 | 72 | 60 | 75 | 61 |
| Operating income | (22) | (50) | (56) | (41) | (74) | (61) |
| Interest expense | – | – | 0 | 3 | 5 | 5 |
| Interest and investment income | – | – | 2 | 7 | 7 | 3 |
| Other non-operating income (expense) | 7 | 0 | 2 | 3 | 3 | (0) |
| Income tax expense | – | – | – | – | – | 0 |
| Net income | (15) | (50) | (54) | (37) | (71) | (61) |
| Net income to common shareholders | (28) | (202) | (54) | (37) | (71) | (61) |